Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Fiocruz/AstraZeneca COVID-19 vaccine at 4, 8, or 12-week intervals
NCT05157178Phase 4Unknown
- Sponsor
- Immunobiological Technology Institute
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Immunobiological Technology Institute. Status: unknown.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05157178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157178.